Cynata receives UK MHRA approval for Phase I trial of CYP-001 to treat GvHD

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to Australian stem-cell and regenerative medicine company, Cynata Therapeutics, to continue its Phase I clinical trial of CYP-001 to treat steroid-resistant graft- …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news